Source comparison
Comparison: MOTS-c vs Standard PCOS Metabolic Interventions
Metformin Inhibits hepatic gluconeogenesis, increases peripheral glucose uptake via AMPK activation (indirect) 1500–2000mg daily oral 20–30% reduction in fasting insulin over 12 weeks Restores ovulation in 40–50% of anovulatory PCOS patients FDA-approved off-l
This comparison does not assign a generated winner or score.
- Metformin
- Inhibits hepatic gluconeogenesis, increases peripheral glucose uptake via AMPK activation (indirect)
- 1500–2000mg daily oral
- 20–30% reduction in fasting insulin over 12 weeks
- Restores ovulation in 40–50% of anovulatory PCOS patients
- FDA-approved off-label for PCOS
- MOTS-c
- Direct AMPK activation in skeletal muscle, independent of insulin receptor signaling
- 5–10mg subcutaneous 3× weekly
- 30–40% reduction in HOMA-IR in animal models; human data pending
- Not yet measured in controlled human trials
- Investigational. Phase I/II equivalent
- Inositol (myo-inositol + d-chiro-inositol)
- Improves insulin receptor signaling, reduces androgen synthesis
- 2000–4000mg daily oral (40:1 ratio)
- 15–25% improvement in insulin sensitivity markers
- Restores ovulation in 30–40% of patients over 6 months
- Dietary supplement. Evidence base moderate
- GLP-1 Agonists (e.g., semaglutide)
- Enhances insulin secretion, slows gastric emptying, reduces appetite
- 0.25–1.0mg subcutaneous weekly
- Weight loss-driven improvement. Indirect insulin sensitivity gain
- Improves ovulation rates through weight reduction and reduced hyperinsulinemia
- Off-label use increasing; not PCOS-specific approval
- The bottom line: MOTS-c targets the same AMPK pathway as metformin but through a distinct mechanism that doesn't rely on insulin receptors. Potentially offering benefit when metformin alone is insufficient. It remains investigational, with no large-scale human trials published yet.